128 related articles for article (PubMed ID: 36184058)
1. The ASTCT-NMDP ACCESS Initiative: A Collaboration to Address and Sustain Equal Outcomes for All across the Hematopoietic Cell Transplantation and Cellular Therapy Ecosystem.
Auletta JJ; Sandmaier BM; Jensen E; Majhail NS; Knutson J; Nemecek E; Ajayi-Hackworth F; Davies SM;
Transplant Cell Ther; 2022 Dec; 28(12):802-809. PubMed ID: 36184058
[TBL] [Abstract][Full Text] [Related]
2. Proceedings of the 2023 Second Annual ASTCT-NMDP ACCESS Initiative Workshop.
Auletta JJ; Holter-Chakrabarty J; Jain T; Miller B; Ward E; Khera N; Gomez-Arteaga A; Hall A; Nemecek E; Robb D; Yusuf RA; Davies SM;
Transplant Cell Ther; 2023 Dec; 29(12):739-746. PubMed ID: 37805142
[TBL] [Abstract][Full Text] [Related]
3. Assessing Medicaid Coverage for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy: A Project from the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program ACCESS Initiative.
Auletta JJ; Khera N; DeMartino P; Kelkar AH; Yusuf RA; Davies SM; Knutson J; Beaver E; Maloney A; Majhail NS
Transplant Cell Ther; 2023 Nov; 29(11):713-720. PubMed ID: 37579920
[TBL] [Abstract][Full Text] [Related]
4. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies.
Nikiforow S; Frigault MJ; Frey NV; Gardner RA; Komanduri KV; Perales MA; Kebriaei P; Warkentin PI; Pasquini M; Aho JL; Levine BL; Heslop HE; Hlucky TL; Habucky K; Gharibo M; Jagasia M; Locke FL
Transplant Cell Ther; 2023 Apr; 29(4):228-239. PubMed ID: 36709800
[TBL] [Abstract][Full Text] [Related]
5. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy.
Kanate AS; Majhail NS; Savani BN; Bredeson C; Champlin RE; Crawford S; Giralt SA; LeMaistre CF; Marks DI; Omel JL; Orchard PJ; Palmer J; Saber W; Veys PA; Carpenter PA; Hamadani M
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1247-1256. PubMed ID: 32165328
[TBL] [Abstract][Full Text] [Related]
6. The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment.
Majhail NS; Murphy EA; Denzen EM; Ferguson SS; Anasetti C; Bracey A; Burns L; Champlin R; Hubbard N; Markowitz M; Maziarz RT; Medoff E; Neumann J; Schmit-Pokorny K; Weisdorf DJ; Yolin Raley DS; Chell J; Snyder EL
Biol Blood Marrow Transplant; 2012 Feb; 18(2):172-82. PubMed ID: 22178961
[TBL] [Abstract][Full Text] [Related]
7. Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program.
Pidala J; Mupfudze TG; Payton T; Barker J; Perales MA; Shaw BE; Fernández-Viña M; Burns LJ; Dehn J
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2501-2506. PubMed ID: 31419569
[TBL] [Abstract][Full Text] [Related]
8. The National Marrow Donor Program: improving access to hematopoietic cell transplantation.
Walker T; Milford E; Chell J; Maiers M; Confer D
Clin Transpl; 2011; ():55-62. PubMed ID: 22755401
[TBL] [Abstract][Full Text] [Related]
9. The Transplantation Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Transplantation Patients.
Wall SA; Olin R; Bhatt V; Chhabra S; Munshi P; Hacker E; Hashmi S; Hassel H; Howard D; Jayani R; Lin R; McCurdy S; Mishra A; Murthy H; Popat U; Wood W; Rosko AE; Artz A
Transplant Cell Ther; 2023 Oct; 29(10):632.e1-632.e10. PubMed ID: 37137442
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Children with Malignancies for Blood and Marrow Transplantation: A Report from the ASTCT Committee on Practice Guidelines.
Fraint E; Abdel-Azim H; Bhatt NS; Broglie L; Chattha A; Kohorst M; Ktena YP; Lee MA; Long S; Qayed M; Sharma A; Stefanski H; Vatsayan A; Wray L; Hamadani M; Carpenter PA
Transplant Cell Ther; 2023 May; 29(5):293-301. PubMed ID: 36775202
[TBL] [Abstract][Full Text] [Related]
11. Challenges and potential solutions for recruitment and retention of hematopoietic cell transplantation physicians: the National Marrow Donor Program's System Capacity Initiative Physician Workforce Group report.
Burns LJ; Gajewski JL; Majhail NS; Navarro W; Perales MA; Shereck E; Selby GB; Snyder EL; Woolfrey AE; Litzow MR
Biol Blood Marrow Transplant; 2014 May; 20(5):617-21. PubMed ID: 24508838
[TBL] [Abstract][Full Text] [Related]
12. Recognition of Hematopoietic Stem Cell Transplantation and Cellular Therapy Expertise to Promote Care Accessibility: A Formally Credentialed Area of Focused Competence in Canada.
Lachance S; Gomes MM; Bambace NM; Bittencourt H; Lepic K; Shafey M; Karpinski J; Guilcher GMT
Transplant Cell Ther; 2021 Sep; 27(9):702-706. PubMed ID: 34153503
[TBL] [Abstract][Full Text] [Related]
13. Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program.
Yusuf RA; Preussler JM; Meyer CL; Schoeppner K; Sees Coles JA; Ruffin A; McCann M; Devine SM; Auletta JJ
Best Pract Res Clin Haematol; 2023 Jun; 36(2):101480. PubMed ID: 37353289
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative.
Denzen EM; Majhail NS; Stickney Ferguson S; Anasetti C; Bracey A; Burns L; Champlin R; Chell J; Leather H; Lill M; Maziarz RT; Medoff E; Neumann J; Schmit-Pokorny K; Snyder EL; Wiggins L; Yolin Raley DS; Murphy EA
Biol Blood Marrow Transplant; 2013 Jan; 19(1):4-11. PubMed ID: 23078785
[TBL] [Abstract][Full Text] [Related]
15. The National Marrow Donor Program's symposium on patient advocacy in cellular transplantation therapy: addressing barriers to hematopoietic cell transplantation.
Murphy EA; Ferguson SS; Omondi NA; Getzendaner LC; Gajewski JL; Goldstein GA; Wingard JR; Rizzo JD; Majhail NS
Biol Blood Marrow Transplant; 2010 Feb; 16(2):147-56. PubMed ID: 20142045
[TBL] [Abstract][Full Text] [Related]
16. Efforts of the United States' National Marrow Donor Program and Registry to improve utilization and representation of minority donors.
Johansen KA; Schneider JF; McCaffree MA; Woods GL;
Transfus Med; 2008 Aug; 18(4):250-9. PubMed ID: 18783584
[TBL] [Abstract][Full Text] [Related]
17. Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics.
Hong S; Majhail NS
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):275-280. PubMed ID: 34889386
[TBL] [Abstract][Full Text] [Related]
18. ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies.
Gardner RA; White C; Elsallab M; Farnia S; Fraint E; Grilley B; Bateman-House A; Grupp SA; Kenderian S; Locke FL; Nikiforow S; Oluwole OO; Rouce RH; Spiegel J; Shah NN; Sharma A; Komanduri K; Gill S
Transplant Cell Ther; 2024 May; ():. PubMed ID: 38762057
[TBL] [Abstract][Full Text] [Related]
19. Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy.
Kanate AS; Majhail N; DeFilipp Z; Dhakal B; Dholaria B; Hamilton B; Herrera AF; Inamoto Y; Jain T; Perales MA; Carpenter PA; Hamadani M
Transplant Cell Ther; 2023 Oct; 29(10):594-597. PubMed ID: 37422194
[TBL] [Abstract][Full Text] [Related]
20. American Society for Transplantation and Cellular Therapy Series, #6: Management of Invasive Candidiasis in Hematopoietic Cell Transplantation Recipients.
Neofytos D; Steinbach WJ; Hanson K; Carpenter PA; Papanicolaou GA; Slavin MA
Transplant Cell Ther; 2023 Apr; 29(4):222-227. PubMed ID: 36649748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
